|The Renal Cell Carcinoma Marker, Aminopeptidase A n/a (Catalog #MBS6004495) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Renal Cell Carcinoma Marker, Aminopeptidase A reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Renal Cell Carcinoma Marker, Aminopeptidase A can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC).
Suitable for use in Immunohistochemistry.
Dilution: Immunohistochemistry (Frozen): 1:10 using the Indirect Immunoperoxidase method. Dilute in PBS. Researchers should empirically determine the suitability of the Renal Cell Carcinoma Marker, Aminopeptidase A n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
"Monoclonal antibody (MAb) RC38 recognizes a human renal antigen of 160 kD recently identified as human aminopeptidase A (APA; EC 184.108.40.206). This ectoenzyme is able to hydrolyse selectively N-terminal glutamyl and aspartyl residues from oligopeptides. By enzyme histochemistry, APA activity has also been localized in the microvessels of all organs in animals and man. A study was done to investigate the distribution of human APA as recognized by MAb RC38 in the microvasculature of normal human tissues and pathological conditions associated with neovascularization. Unexpectedly, in normal tissues vascular staining with MAb RC38 was generally weak and often absent, while in tumors, granulation tissue, and chronic synovitis, marked microvascular staining was demonstrated. By immuno-electron microscopy, the antigen was found on the cell membrane of activated pericytes and their processes in the tumor vasculature. RC38 expression could not be detected on cultured human endothelial cells or pericytes. These observations suggest that pericyte expression of a subtype of APA (as recognized by MAb RC38) is markedly enhanced in the vasculature of tumors and wound healing tissue as compared with normal resting tissues. This provides further evidence of the altered state of pericytes in these conditions. Pericyte APA may be involved in the metabolism of biologically active oligopeptides during neovascularization, supporting a regulatory role of pericytes in this process. In addition, MAb RC38 may be useful as a marker of pericyte activation in tissue sections.
Immunogen: Renal Cell Carcinoma. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Renal Cell Carcinoma Marker, Aminopeptidase An are readily searchable from our website. Different antibodies against the same target such as Renal Cell Carcinoma Marker, Aminopeptidase A may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.